Bio Green Med Solution (BGMS)
Market Price (3/18/2026): $0.901 | Market Cap: $1.7 MilSector: Health Care | Industry: Biotechnology
Bio Green Med Solution (BGMS)
Market Price (3/18/2026): $0.901Market Cap: $1.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -218% | Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -156% | Penny stockMkt Price is 0.9 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -97% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11325% | |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2188% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7522%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7522% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -313% | ||
| High stock price volatilityVol 12M is 124% | ||
| Key risksBGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -218% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -97% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -156% |
| Penny stockMkt Price is 0.9 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11325% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2188% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7522%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7522% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -313% |
| High stock price volatilityVol 12M is 124% |
| Key risksBGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bio Green Med Solution (BGMS) stock has lost about 40% since 11/30/2025 because of the following key factors:
1. Strategic Shift to Fire Safety and Limited Revenue Generation.
Bio Green Med Solution (BGMS) fully transitioned its core business from biopharmaceuticals to fire safety protection and distribution activities as of September 2025, following the acquisition of FITTERS Sdn. Bhd.. Simultaneously, the company sold patent rights for key biopharmaceutical assets and ceased related research and development, resulting in zero R&D expenses by the third quarter of 2025. Despite this strategic shift, the new fire safety segment generated only $81,000 in product revenue for the three months ended September 30, 2025, indicating a minimal revenue stream from its new primary operations, which likely contributed to investor uncertainty and downward pressure on the stock since November 30, 2025.
2. Precarious Financial Health and Insufficient Cash Runway.
The company reported a net loss of $1.0 million for the third quarter of 2025 and a significantly negative net profit margin of -1219.8%. As of September 30, 2025, Bio Green Med Solution held $3.8 million in cash and cash equivalents, which it estimated would only fund planned expenditures into the first quarter of 2026. This limited cash runway and ongoing losses signal potential liquidity issues and a need for further financing, contributing to investor apprehension.
Show more
1. Strategic Shift to Fire Safety and Limited Revenue Generation.
Bio Green Med Solution (BGMS) fully transitioned its core business from biopharmaceuticals to fire safety protection and distribution activities as of September 2025, following the acquisition of FITTERS Sdn. Bhd.. Simultaneously, the company sold patent rights for key biopharmaceutical assets and ceased related research and development, resulting in zero R&D expenses by the third quarter of 2025. Despite this strategic shift, the new fire safety segment generated only $81,000 in product revenue for the three months ended September 30, 2025, indicating a minimal revenue stream from its new primary operations, which likely contributed to investor uncertainty and downward pressure on the stock since November 30, 2025.
2. Precarious Financial Health and Insufficient Cash Runway.
The company reported a net loss of $1.0 million for the third quarter of 2025 and a significantly negative net profit margin of -1219.8%. As of September 30, 2025, Bio Green Med Solution held $3.8 million in cash and cash equivalents, which it estimated would only fund planned expenditures into the first quarter of 2026. This limited cash runway and ongoing losses signal potential liquidity issues and a need for further financing, contributing to investor apprehension.
Show more
Stock Movement Drivers
Fundamental Drivers
The -38.8% change in BGMS stock from 11/30/2025 to 3/17/2026 was primarily driven by a -38.8% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3172026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.51 | 0.92 | -38.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 35.7 | 21.8 | -38.8% |
| Shares Outstanding (Mil) | 2 | 2 | 0.0% |
| Cumulative Contribution | -38.8% |
Market Drivers
11/30/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| BGMS | -38.8% | |
| Market (SPY) | -1.8% | 34.9% |
| Sector (XLV) | -5.1% | 13.4% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| BGMS | ||
| Market (SPY) | 4.3% | 27.4% |
| Sector (XLV) | 9.4% | 5.2% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/17/2026| Return | Correlation | |
|---|---|---|
| BGMS | ||
| Market (SPY) | 13.9% | 27.4% |
| Sector (XLV) | 1.8% | 5.2% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/17/2026| Return | Correlation | |
|---|---|---|
| BGMS | ||
| Market (SPY) | 75.6% | 27.4% |
| Sector (XLV) | 23.1% | 5.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BGMS Return | - | - | - | - | -72% | -38% | -82% |
| Peers Return | -33% | -38% | -29% | -55% | -48% | 14% | -92% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -2% | 78% |
Monthly Win Rates [3] | |||||||
| BGMS Win Rate | - | - | - | - | 0% | 0% | |
| Peers Win Rate | 31% | 44% | 44% | 36% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| BGMS Max Drawdown | - | - | - | - | -77% | -44% | |
| Peers Max Drawdown | -40% | -52% | -49% | -60% | -61% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/17/2026 (YTD)
How Low Can It Go
BGMS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bio Green Med Solution (BGMS)
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
AI Analysis | Feedback
A small, early-stage Merck, but purely focused on developing new cancer drugs that are still in clinical trials.
Like a startup biotech aiming to discover the next breakthrough cancer treatment, similar to an early-stage Gilead Sciences.
Moderna, but for oncology drugs that are currently in clinical development, rather than vaccines.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer
Datuk Dr. Doris Wong Sing Ee was elected as the Chief Executive Officer and Executive Director of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025 after acquiring a controlling 70% stake in the company. She brings over 20 years of experience in various industries. Since October 2020, she has served as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been responsible for optimizing financial operations, establishing business goals, advising the board of directors on organizational activities, and executing special business projects. Dr. Wong has also been involved in various investment opportunities focused on business diversification, revenue generation, and increasing shareholders' wealth. Prior to her appointment at Cyclacel, she served as an independent director and a member of the audit and compensation committees of Energem Corp from November 2021 until January 2023.
Kiu Cu Seng, Chief Financial Officer
Kiu Cu Seng was appointed as Executive Director, Secretary, and Chief Financial Officer of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025. He brings significant accounting and audit experience to the company.
AI Analysis | Feedback
The public company Bio Green Med Solution (symbol: BGMS) faces several key risks, primarily stemming from its nature as a clinical-stage biopharmaceutical company, as described in the provided background information. Here are the key risks:- Clinical Trial and Regulatory Approval Risk: The most significant risk for Bio Green Med Solution, based on the description, is the inherent uncertainty and high failure rate associated with clinical trials and the subsequent regulatory approval process for new drug candidates. The company's development programs, including fadraciclib, CYC140, Sapacitabine, and seliciclib, are all in Phase 1/2 clinical trials or investigator-sponsored trials. There is no guarantee that these drug candidates will demonstrate sufficient efficacy or safety in later-stage trials, or that they will ultimately receive the necessary regulatory approvals from health authorities like the FDA to be commercialized. Failure at any stage of development or inability to obtain approval would severely impact the company's prospects.
- Product Pipeline and Development Stage Risk: As a clinical-stage biopharmaceutical company, Bio Green Med Solution, as described, does not currently have any approved commercial products. Its future success and ability to generate revenue are entirely dependent on the successful development, approval, and commercialization of its pipeline candidates. If none of these candidates reach the market, the company would lack a sustainable revenue stream.
- Funding and Capital Needs: The research and development of pharmaceutical products, especially through extensive clinical trials, are highly capital-intensive processes. Bio Green Med Solution, as described, requires substantial ongoing funding to advance its various drug development programs. There is a risk that the company may not be able to secure adequate additional financing on favorable terms, or at all, which could lead to delays, curtailment, or even discontinuation of critical research and development efforts.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Capital Allocation Decisions (Bio Green Med Solution, Inc. - BGMS)
Share Issuance
- Bio Green Med Solution, Inc. implemented a 1-for-15 reverse stock split on its common stock, effective July 7, 2025, to meet Nasdaq bid price requirements. This action reduced the number of outstanding common shares from 23,759,475 to 1,583,965.
- The company executed other reverse stock splits, including a 1-for-15 split on December 18, 2023, and a 1-for-16 split on May 12, 2025.
- Bio Green Med Solution entered into multiple Warrant Exchange Agreements where existing warrants to purchase common stock were exchanged for newly issued common shares.
Inbound Investments
- Around late 2024/early 2025, there was an investment of $3.1 million in Preferred Stock, concurrently with the appointment of an Interim CEO.
Outbound Investments
- In September 2025, Bio Green Med Solution, Inc. completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based company specializing in fire safety and protection solutions, diversifying its business portfolio. As part of this Exchange Transaction, BGMS issued 699,158 shares of its common stock, representing 19.99% of its then-issued and outstanding common stock, in exchange for all of Fitters' equity interests.
- On October 6, 2025, the company acquired Assets and Rights of Plogosertib from Tethra Biosciences Inc. for $0.47 million.
Capital Expenditures
- Bio Green Med Solution Inc reported $0 in capital expenditures for Q3 2024.
- The company also reported $0 in capital expenditures for several quarters, including June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Can Bio Green Med Solution Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BGMS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.09 |
| Mkt Cap | 0.0 |
| Rev LTM | 0 |
| Op Inc LTM | -7 |
| FCF LTM | -5 |
| FCF 3Y Avg | -10 |
| CFO LTM | -5 |
| CFO 3Y Avg | -10 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.2% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 359.8% |
| QoQ Delta Rev Chg LTM | 356.2% |
| Op Mgn LTM | -5,643.4% |
| Op Mgn 3Y Avg | -6,614.0% |
| QoQ Delta Op Mgn LTM | 46,147.0% |
| CFO/Rev LTM | -3,746.0% |
| CFO/Rev 3Y Avg | -4,362.5% |
| FCF/Rev LTM | -3,747.8% |
| FCF/Rev 3Y Avg | -4,364.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 15.7 |
| P/EBIT | -0.1 |
| P/E | -0.1 |
| P/CFO | -0.1 |
| Total Yield | -309.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4,601.7% |
| D/E | 0.0 |
| Net D/E | -2.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.3% |
| 3M Rtn | 1.7% |
| 6M Rtn | 10.6% |
| 12M Rtn | 0.3% |
| 3Y Rtn | 15.4% |
| 1M Excs Rtn | 3.0% |
| 3M Excs Rtn | 3.9% |
| 6M Excs Rtn | 9.1% |
| 12M Excs Rtn | -18.0% |
| 3Y Excs Rtn | -58.5% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | 0 | ||||
| Total | 0 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | -25 | ||||
| Total | -25 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | -23 | ||||
| Total | -23 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Development of innovative cancer medicines based on cell cycle, transcriptional regulation and | 28 | 43 | 46 | 15 | |
| Total | 28 | 43 | 46 | 15 |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -2.2% | -8.2% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 1 |
| # Negative | 1 | 1 | 0 |
| Median Positive | 0.0% | ||
| Median Negative | -2.2% | -8.2% | |
| Max Positive | 0.0% | ||
| Max Negative | -2.2% | -8.2% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/02/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/29/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yap, Kim Choy | Direct | Sell | 11052025 | 1.70 | 28,540 | Form | |||
| 2 | Yap, Kim Choy | Direct | Sell | 11032025 | 1.81 | 112,260 | 202,854 | 51,500 | Form | |
| 3 | Kua, Khai Loon | Direct | Sell | 11032025 | 1.80 | 242,477 | Form | |||
| 4 | Ong, Yee Lung | Direct | Sell | 11032025 | 1.80 | 248,814 | Form | |||
| 5 | Yap, Kim Choy | Direct | Sell | 10312025 | 1.83 | 110,749 | 203,114 | 258,154 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.